Background: Molnupiravir is an oral prodrug with antiviral activity against severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2). Molnupiravir was initially developed for …

Background At the peak of the coronavirus disease 2019 (COVID-19) pandemic, the need
for an orally administered agent to prevent the progression of acute respiratory syndrome …

Background Safe and effective oral treatments are needed to improve clinical outcomes for
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small …

Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …

Background The role of molnupiravir for coronavirus disease 2019 (COVID-19) treatment is
unclear. Methods We conducted a systematic review until 1 November 2022 searching for …

Purpose Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …

Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

The coronavirus disease (COVID-19) pandemic, caused by the spread of the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), marked its debut in 2019. To date, this …

The global COVID-19 pandemic is currently underway. To date, there are approximately
4.55 million deaths and 219 million people infected [1]. The massive vaccination campaign …

Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …